“Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01% Tazarotene 0.045% Lotion”. SKIN The Journal of Cutaneous Medicine 4, no. 6 (October 27, 2020): s79. Accessed May 9, 2025. https://skin.dermsquared.com/skin/article/view/1112.